Several clinical trials have demonstrated the effectiveness of prophylactic administration of selective oestrogen receptor modulators (SERMs) such as tamoxifen ([Fisher *et al*, 2005](#bib13){ref-type="other"}; [Cuzick *et al*, 2007](#bib6){ref-type="other"}; [Powles *et al*, 2007](#bib35){ref-type="other"}; [Veronesi *et al*, 2007b](#bib44){ref-type="other"}) and raloxifene ([Cauley *et al*, 2001](#bib3){ref-type="other"}; [Martino *et al*, 2004](#bib27){ref-type="other"}; [Vogel *et al*, 2006](#bib45){ref-type="other"}) in reducing incidence of breast cancer among women at high risk of developing the disease. Tamoxifen was approved for prophylaxis by the US Food and Drug Administration in 1998, and raloxifene was also approved for postmenopausal women in 2007.

Tamoxifen reduces the risk of breast cancer whereas increasing the risk of adverse events such as endometrial cancer and pulmonary embolism. Raloxifene is a second-generation SERM usually used for osteoporosis treatment, and it reduces the risk of invasive breast cancer with a lower risk of known adverse events associated with SERMs, compared to tamoxifen. This is because raloxifene does not induce the unwanted stimulation of endometrium ([Delmas *et al*, 1997](#bib9){ref-type="other"}). Therefore, raloxifene is considered to have a better clinical property as prophylactic agent, although it is inferior to tamoxifen in preventing noninvasive breast cancer. More women at high risk of developing breast cancer are expected to take raloxifene as their breast cancer prevention drug in the United States ([Bevers, 2007](#bib2){ref-type="other"}).

However, both of these agents have been neither approved nor made available for its use as breast cancer prevention in Japan, although experts have shown their expectations ([Iwata and Saeki, 2006](#bib22){ref-type="other"}). It is said that there are five hurdles to overcome in addressing intervention in the diffusion process of new drug: quality, safety, efficacy, cost-effectiveness, and affordability ([Trueman *et al*, 2001](#bib41){ref-type="other"}). This paper aims to present evidence to the fourth hurdle, cost-effectiveness of both agents, under Japan\'s health system. Although cost-effectiveness of prophylactic use of tamoxifen has been reported from the USA ([Noe *et al*, 1999](#bib33){ref-type="other"}; [Grann *et al*, 2000](#bib19){ref-type="other"}; [Smith and Hillner, 2000](#bib40){ref-type="other"}; [Hershman *et al*, 2002](#bib20){ref-type="other"}; [Melnikow *et al*, 2006](#bib29){ref-type="other"}) and Australia ([Eckermann *et al*, 2003](#bib12){ref-type="other"}), that of raloxifene has not been published to date except as a part of economic evaluation of osteoporosis management ([Armstrong *et al*, 2001](#bib1){ref-type="other"}; [Kanis *et al*, 2005](#bib25){ref-type="other"}). This paper also simulates a therapeutic policy switch from tamoxifen to raloxifene among postmenopausal women to illustrate the relative value of raloxifene. Consequently, it should have implications to the developed countries where chemoprevention with tamoxifen is already in practise.

Methods
=======

We conduct a cost-effectiveness analysis with Markov modelling based on the findings of the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial ([Fisher *et al*, 2005](#bib13){ref-type="other"}), the NSABP P-2 trial ([Vogel *et al*, 2006](#bib45){ref-type="other"}), and the literature on costing under Japan\'s health system including sensitivity analyses from societal perspective. Although longer follow-up results for tamoxifen are reported from the first International Breast Cancer Intervention Study (IBIS-I; [Cuzick *et al*, 2007](#bib6){ref-type="other"}) and the Royal Marsden trial ([Powles *et al*, 2007](#bib35){ref-type="other"}), NSABP P-1 trial with a shorter follow-up period is chosen as clinical evidence for our modelling to make clear comparisons with NSABP P-2 trial of raloxifene. The long-term outcomes for tamoxifen ([Veronesi *et al*, 2007a](#bib43){ref-type="other"}) are considered in our sensitivity analyses. We use TreeAge Pro 2008 (TreeAge Software Inc.) for our economic modelling.

High-risk women
---------------

We model high-risk women according to the risk classifications featured in the report of clinical trials: three levels (⩾1.66, 3.01--5.00%, ⩾5.01%) of a 5-year predicted breast cancer risk, with a history of lobular carcinoma *in situ* (LCIS), and with a history of atypical hyperplasia (AH). A 5-year predicted breast cancer risk of an individual woman used in the trials is based on Gail *et al* model 2 ([Gail and Costantino, 2001](#bib16){ref-type="other"}), which is validated for white women ([Rockhill *et al*, 2001](#bib36){ref-type="other"}) and African American women ([Gail *et al*, 2007](#bib17){ref-type="other"}), to date. We assume the same model is good for Japanese women.

We also model the ages of starting prophylaxis: 35, 50, 60 years old for tamoxifen, and 50, 60 years old for raloxifene taking the menopause into account.

Markov model
------------

We construct a Markov model of courses followed by high-risk women, which is shown in [Figure 1](#fig1){ref-type="fig"}. Eight health states are modelled according to clinical events monitored and found significant in P-1 trial and P-2 trial: (1) healthy; (2) invasive breast cancer; (3) noninvasive breast cancer, (4) endometrial cancer; (5) pulmonary embolism; (6) cataract; (7) hip fracture; and (8) dead. Healthy women at high risk of the disease, women with invasive and noninvasive breast cancer are the target health states for chemoprevention. An increase in risk of endometrial cancer, pulmonary embolism, and cataract are known as adverse effects of SERMs, whereas a decrease in risk of hip fracture is known as a beneficial effect. Transitions between health states are indicated with arrows.

The time span of each stage is set at 1 year, since trials report annual incidence rates. Markov process is repeated until death or age 100, whichever comes first, since all events are expected to occur within this time horizon. Women who survive after the age of 100 years are assumed to die regardless of breast cancer development.

Chemoprevention
---------------

Prophylaxis with SERMs is continued for 5 years, or discontinued in case of adverse events, which is similar to the regimen employed in clinical trials.

Comparisons
-----------

We compare outcomes and costs in terms of incremental cost-effectiveness ratios (ICERs) between *status quo* in Japan, without prophylaxis, and hypothetical practise, with prophylaxis, by the agent (tamoxifen and raloxifene), the risk classification, and the age of starting prophylaxis. We also compare prophylaxis with tamoxifen and prophylaxis with raloxifene to estimate the relative value of raloxifene to tamoxifen, although this does not depict any marginal change in Japan.

Outcome estimation
------------------

Outcomes in terms of life years gained (LYGs) and quality adjusted life years (QALYs) are estimated by assigning transitional probabilities and utility weights to Markov model from the literature.

Transitional probabilities from healthy state to disease states in Markov model are shown in [Table 1](#tbl1){ref-type="table"} according to the findings from the clinical trials. Risk reduction effect of SERMs is assumed to continue during the 5-year course of prophylaxis.

[Table 2](#tbl2){ref-type="table"} summarises other assumptions such as transitional probabilities from disease states to dead state and utility weights used in Markov model. The share of clinical stages of invasive breast cancer at diagnosis are adopted from a nationwide survey on breast cancer screening ([Japan Cancer Society, 2007](#bib23){ref-type="other"}), of which prognosis is calculated from corresponding follow-up cases at Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital. The prognosis of endometrial cancer is also adopted from a nationwide cancer registry ([Japanese Society of Obstetrics and Gynecology, 2000](#bib24){ref-type="other"}). The prognosis of pulmonary embolism and hip fracture are taken from [Sakuma *et al* (2004)](#bib38){ref-type="other"}; [Kitamura *et al* (1998)](#bib26){ref-type="other"}, respectively. Japanese female population mortality rates from Vital Statistics ([Ministry of Health, Labour and Welfare, 2005a](#bib30){ref-type="other"}) are applied for other transitions to dead state.

It is more preferable to adopt utility weights from a consistent study that assesses our six disease states in Japan, but there is no Japanese utility weight in the literature to date, which may be applied to any health states in our model. To illustrate the typical patient states, we adopt the weights assessed in developed countries considering them as the best available knowledge, and choosing them under the consensus of staff doctors at Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital ([de Koning *et al*, 1991](#bib8){ref-type="other"}; [Hillner *et al*, 1993](#bib21){ref-type="other"}; [Smith and Hillner, 1993](#bib39){ref-type="other"}; [Grann *et al*, 1998](#bib18){ref-type="other"}; [Earle *et al*, 2000](#bib11){ref-type="other"}; [Armstrong *et al*, 2001](#bib1){ref-type="other"}; [Chau *et al*, 2003](#bib4){ref-type="other"}; [Cykert *et al*, 2004](#bib7){ref-type="other"}; [Naeim and Keeler, 2005](#bib32){ref-type="other"}; [Ruof *et al*, 2005](#bib37){ref-type="other"}).

Outcome is discounted at a rate of 3%.

Costing
-------

From societal perspective, costing should cover the opportunity cost borne by various economic entities in the society. In the context of this study, costs borne by women or third party payers including the government and social insurers are considered, although there is no particular assumption about who bears the cost of chemoprevention. According to the national medical care fee schedule, the amount of direct payments to health-care providers is estimated as cost, whereas costs to sectors other than health and productivity losses are left uncounted.

Health states are identified as cost items in Markov model. [Table 3](#tbl3){ref-type="table"} summarises the cost of each health states. Being in healthy state, women with chemoprevention take 20 mg per day, ¥82.6 (£0.41; £1=¥200), of tamoxifen, or 60 mg per day, ¥148.5 (£0.74), of raloxifene, prescribed regularly for 5 years, and annual mammography checkup. Women without chemoprevention also undergo annual mammography checkup. Although the state is labelled as 'healthy\', it includes all other diseases that are not modelled in Markov model. Annual treatment costs by the age stratum are approximated by annual health-care expenditure per woman adopted from National Health-Care Expenditure ([Ministry of Health, Labour and Welfare, 2005b](#bib31){ref-type="other"}). As it is well known that the cost of health care in the last year of life tends to be large, these are shown separately after an adjustment based on [Fukawa (1998)](#bib15){ref-type="other"}.

[Table 3](#tbl3){ref-type="table"} also summarises the treatment cost of invasive breast cancer by the age stratum. In the case of cancer care, the cost in the first year after diagnosis tends to be large as well as in the last year of life, so here again, the costs are shown separately. These figures are obtained from insurance claim reviews at Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital. As to the cost of the first year, recent breast cancer cases of stage I and stage II that have undergone initial treatment with a follow-up of 1 year are retrospectively selected so that each age strata has 40 cases. As to the yearly cost of the second year and thereafter, 40 cases for each age strata are randomly selected from follow-up cases initially diagnosed as stage I and stage II. As to the cost of the last year of life, recent 80 fatal cases are retrospectively selected, as the number of these is relatively limited. Insurance claims of these total of 400 cases for 1 year are reviewed to calculate average annual costs by the age strata. Then an adjustment is made to include the cost of prescription to be filled at external pharmacies, such as in the case of adjuvant hormonal therapy, which is based on the consensus among staff doctors.

Costs of disease states are summarised in [Table 3](#tbl3){ref-type="table"} as well. Treatment costs of noninvasive breast cancer, endometrial cancer, cataract, and hip fractures are adopted from a background study for the development of Japanese prospective payment system to health-care providers, diagnosis procedure combination ([Matsuda and Ishikawa, 2003](#bib28){ref-type="other"}), whereas treatment cost of pulmonary embolism is adopted from [Fuji *et al* (2005)](#bib14){ref-type="other"}.

Costs are also discounted at a rate of 3%.

Sensitivity analyses
--------------------

To deal with the uncertainty of probabilities, utility weights, and costs used in our economic model, one-way sensitivity analyses are performed. Transitional probabilities from healthy state to disease states shown in [Table 1](#tbl1){ref-type="table"} are varied in 1.5 times of 95% confidence intervals (CI) reported from the clinical trials. 95% CI is often used for similar exercises of sensitivity analyses, but we set wider range for the applicability of the clinical trial data to Japanese women. The other probabilities shown in [Table 2](#tbl2){ref-type="table"} are changed by ±50%. Utility weights are changed by ±20%, and we think this could cover the difference between the utility weights of Japanese women and those of the other developed nations. Costs shown in [Table 3](#tbl3){ref-type="table"} are changed by ±50%. Discount rate is also changed from 0 to 6%.

Acknowledging the long-term outcomes for tamoxifen in the IBIS-I trial ([Cuzick *et al*, 2007](#bib6){ref-type="other"}) and the Royal Marsden trial ([Powles *et al*, 2007](#bib35){ref-type="other"}), risk reduction effect of tamoxifen is prolonged from 5 to 10 and 15 years without any risk increase of adverse events after the completion of prophylaxis.

Results
=======

Outcomes
--------

[Table 4](#tbl4){ref-type="table"} shows the results of cost-effectiveness analysis comparing prophylaxis with no prophylaxis.

In the comparison between prophylaxis with tamoxifen *vs* no prophylaxis, most outcomes in terms of LYGs are increased by chemoprevention except for women with a 5-year predicted breast cancer risk of ⩾1.66% starting at age 50, and women with a 5-year predicted breast cancer risk of 3.01--5.00% starting at age 50 and 60. Outcomes in terms of QALYs are also increased except for women with a 5-year predicted breast cancer risk of ⩾1.66% starting at age 50 and 60, women with a 5-year predicted breast cancer risk of 3.01--5.00%, and women with a history of LCIS starting at age 60. The largest outcome gain in terms of QALYs, 0.105, is estimated among women with a history of AH starting at age 35.

Between prophylaxis with raloxifene *vs* no prophylaxis, all outcomes in terms of LYGs are increased by chemoprevention. Outcomes in terms of QALYs are increased except for women with a 5-year predicted breast cancer risk of ⩾1.66%, and women with a 5-year predicted breast cancer risk of 3.01--5.00%. The largest outcome gain in terms of QALYs, 0.058, is estimated among women with a history of AH starting at age 50.

[Table 5](#tbl5){ref-type="table"} shows the results of cost-effectiveness analysis of therapeutic policy switch from tamoxifen to raloxifene.

Raloxifene is consistently superior to tamoxifen across presented risk classifications and starting ages of prophylaxis.

Costs
-----

In the comparison between prophylaxis with tamoxifen *vs* no prophylaxis ([Table 4](#tbl4){ref-type="table"}), cost savings are estimated in higher risk classifications, among women with a history of LCIS or AH, starting at younger age. The largest saving, ¥367 901 (£1840), is estimated among women with a history of AH starting at age 35.

Between prophylaxis with raloxifene *vs* no prophylaxis, prophylaxes are found more costly. A cost saving of ¥10 387 (£52) is estimated among women with a history of AH starting at age 50.

When considering the therapeutic policy switch ([Table 5](#tbl5){ref-type="table"}), the use of raloxifene is consistently more costly than tamoxifen, as anticipated by the difference in price of agents.

Cost-effectiveness
------------------

There is a suggested criterion for cost-effectiveness in Japan ([Ohkusa, 2003](#bib34){ref-type="other"}) to be ¥6000 000 (£30 000) for one QALY gain, and both [Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"} report judgements with this criterion.

In the comparison between prophylaxis with tamoxifen *vs* no prophylaxis, favourable results, that is 'cost less and gain more\' or cost-effective, are obtained in higher risk classifications starting at younger age. Those are: women with a history of AH regardless of starting age, women with a history of LCIS starting at age 35 and 50, and women with a 5-year predicted breast cancer risk of ⩾5.01% starting at age 35 and 50.

Similar results are found between prophylaxis with raloxifene *vs* no prophylaxis. Favourable results are: women with a history of AH regardless of starting age, women with a history of LCIS starting at age 50, and women with a 5-year predicted breast cancer risk of ⩾5.01% starting at age 50.

As shown in [Table 5](#tbl5){ref-type="table"}, ICERs for the therapeutic policy switch of prophylactic agent from tamoxifen to raloxifene varies from ¥1839 670 per QALY (£9198 per QALY) to ¥6771 100 per QALY (£33 856 per QALY). The larger ICER is yet still close to the suggested criterion of ¥6000 000 per QALY (£30 000 per QALY).

Stability of cost-effectiveness
-------------------------------

One-way sensitivity analyses produce similar results across the agents, the risk classifications and the ages of starting prophylaxis. Therefore, we draw a cost-effectiveness plane to show the comparison between prophylaxis with raloxifene *vs* no prophylaxis among three risk classifications as an example: women with a 5-year predicted breast cancer risk of ⩾5.01%, women with a history of LCIS, and women with a history of AH.

[Figure 2](#fig2){ref-type="fig"} plots three base-case values and 306 results (102 changes of variables × three different risk classifications). Line OA indicates the threshold of favourable ICER compared to the suggested criterion of ¥6000 000 (£30 000) for one QALY gain. Most results are plotted close to base-case value, which suggest the stability of our model. Results for women with a history of AH remain constantly favourable being cost saving or cost-effective by the change of variables except for one plot shown as in area B. However, several results for women with a 5-year predicted breast cancer risk of ⩾5.01% and for women with a history of LCIS cross the threshold line, the vertical axis or the horizontal axis from the base-case values. Three plots in area B and seven plots in area C indicate that results turn unfavourably, that is cost-ineffective or 'gain less\', whereas plots in area D show that results become cost saving.

Our model is most sensitive to the utility weight for healthy state under chemoprevention, of which plots are drawn in area B. Its change to 0.79 turns incremental effectiveness into negative. Critical values to change the judgement are 0.98, which makes the ICERs of women with a 5-year predicted breast cancer risk of ⩾5.01% and woman with a history of LCIS cost-ineffective, and the value of 0.96 makes women with a history of AH 'gain less\'. The model is also sensitive to the discount rate, of which plot is drawn in area C. Its raise of 5.9 and 4.3% makes the ICERs of women with a 5-year predicted breast cancer risk of ⩾5.01% and women with a history of LCIS cost-ineffective, respectively. The cost of chemoprevention is also influential to the results, of which results are shown in areas C and D. A price increase of more than 30% for raloxifene makes the ICER of women with a history of LCIS cost-ineffective, whereas a price decrease of more than 16 or 29% make the results for women with a 5-year predicted breast cancer risk of ⩾5.01% and women with a history of LCIS cost saving, respectively. Changes of the probabilities of transition to invasive breast cancer, endometrial cancer, and hip fracture are also plotted in areas C and D. Raising the probability of invasive breast cancer beyond 0.00710 and 0.00683 makes the ICERs of women with a 5-year predicted breast cancer risk of ⩾5.01% and women with a history of LCIS cost-ineffective, whereas lowering to less than 0.00456 or 0.00436 make the results for women with a 5-year predicted breast cancer risk of ⩾5.01% and women a history of LCIS cost saving, respectively. Raising the probability of endometrial cancer beyond 0.00369 and 0.00271 makes the ICERs of women with a 5-year predicted breast cancer risk of ⩾5.01% and women with a history of LCIS cost-ineffective, respectively. Raising probability of hip fracture beyond 0.00098 makes the results for women with a history of LCIS cost saving. The other plots in area C reflect a raise of utility weight for invasive breast cancer after the second year.

Prolonging risk reduction effect of tamoxifen from 5 to 10 and 15 years without any risk increase of adverse events after the completion of prophylaxis brings more favourable results. For example, the effect of 10 years results in 'cost less and gain more\' for every risk classification starting at age 35, whereas the effect of 15 years makes no change in the results of 'cost more and gain less\' among women with a 5-year predicted breast cancer risk of ⩾1.66% starting at age 50 and 60.

Discussion
==========

We conduct a cost-effectiveness analysis of SERMs as prophylactic agents against breast cancer among high-risk women by making comparisons between *status quo* in Japan, without prophylaxis, and hypothetical practise, with prophylaxis, by the agent (tamoxifen and raloxifene), the risk classification, and the age of starting prophylaxis.

We find that prophylaxis with tamoxifen results in 'cost less and gain more\' among extremely high-risk women such as those with a 5-year predicted breast cancer risk of ⩾5.01%, those with a history of LCIS, and those with a history of AH starting at age 35 and 50. Prophylaxis with raloxifene is also found 'cost less and gain more\' for women with a history of AH starting at age 50. The younger the age of starting prophylaxis, the more the cost saving and outcome gain. We also find that prophylaxis with tamoxifen for women with a history of AH starting at age 60 results in favourable ICER compared to the suggested criterion of ¥6000 000 (£30 000) for one QALY gain. Prophylaxis with raloxifene is also found cost-effective for women with a 5-year predicted breast cancer risk of ⩾5.01% starting at age 50, those with a history of LCIS starting at age 50 and those with a history of AH starting at age 60. The younger the age of starting prophylaxis, the more favourable the ICER. Within the same risk classification and starting age, raloxifene tends to gain more and cost more compared to tamoxifen. On the contrary, we also find that prophylaxes with tamoxifen or raloxifene for women with a 5-year predicted breast cancer risk of ⩽5.00% tend to result in 'cost more and gain less\'.

These findings are similar to the previous economic evaluations of chemoprevention of breast cancer with tamoxifen including analyses of risk level differences such as [Noe *et al* (1999)](#bib33){ref-type="other"}; [Grann *et al* (2000)](#bib19){ref-type="other"}; [Hershman *et al* (2002)](#bib20){ref-type="other"}; [Melnikow *et al* (2006)](#bib29){ref-type="other"}, although these studies are carried out under the US health system.

Our findings suggest that introduction of chemoprevention with SERMs targeting extremely high-risk women in Japan can be justifiable as an efficient use of finite health-care resources, possibly contributing to cost containment. The cost saving results suggest chemoprevention not only cost-effective but also affordable. Taking the superiority of raloxifene in outcome gain and the difference in indication into account, it is recommendable to administer tamoxifen for premenopausal women and raloxifene for postmenopausal women.

Our economic model is found sensitive to the utility weight for healthy state under chemoprevention, the discount rate and the cost of chemoprevention, in addition to the probabilities of transition to invasive breast cancer, endometrial cancer, or hip fracture. This is anticipated because these variables are supposed to influence the cost-effectiveness of preventive services. We think that our economic model succeeds in explaining the context under consideration.

We also analysed the cost-effectiveness of therapeutic policy switch of agent, tamoxifen to raloxifene among postmenopausal women, although this does not depict any marginal change in Japan. All simulated ICERs by risk classifications starting at age 50 and 60 fall in a favourable level. Due caution is needed in transferring these findings from our Japanese model to other health system ([Drummond and Pang, 2001](#bib10){ref-type="other"}), but it implies that the administration of raloxifene instead of tamoxifen for postmenopausal high-risk women could be economically acceptable in developed countries where chemoprevention with tamoxifen is already in practise.

There are a couple of points to consider when interpreting our results. Our model depends on clinical evidence established in the United States by P-1 and P-2 trial. Composition of ethnicity and life styles of participating women are different from those of Japanese women. This also relates to another point, that is the validity of the 5-year risk prediction model defining high-risk women. As already mentioned in Methods section, it is based on Gail *et al* model 2 ([Gail and Costantino, 2001](#bib16){ref-type="other"}), which has been validated for white women ([Rockhill *et al*, 2001](#bib36){ref-type="other"}) and African American women ([Gail *et al*, 2007](#bib17){ref-type="other"}) only. Our approach is acceptable as to these points, as the results of P-1 and P-2 trial are the best available evidence to date for the objectives of this study, and similar risk factors to Gail *et al* model 2 are identified in a model of individualised probability of developing breast cancer for Japanese women ([Ueda *et al*, 2003](#bib42){ref-type="other"}), and the function of ethnic difference in developing breast cancer is reported as small ([Chen *et al*, 2004](#bib5){ref-type="other"}). Our model also depends on utility weights reported from Western countries, as none of those from Japan are available. However, our findings of consistent outcomes in terms of LYGs offer reasonable conclusions.

In summary, this study suggests that chemoprevention of breast cancer with SERMs targeting high-risk women such as a 5-year predicted breast cancer risk of ⩾5.01%, women with a history of LCIS, and women with a history of AH, clears the hurdles of introducing new intervention by means of cost-effectiveness and affordability, with best available evidence. Although further studies and policy formulations are necessary about breast cancer chemoprevention in Japan, this study also implies that the administration of raloxifene instead of tamoxifen may be cost-effective under the context of developed countries where chemoprevention with tamoxifen has already been adopted.

This study is funded by Japan\'s Ministry of Health, Labour, and Welfare research grant, a study on the construction of algorithm of multimodality therapy with biomarkers for primary breast cancer by a formulation of the decision-making process, led by Masakazu Toi (H18-3JIGAN-IPPAN-007). We appreciate Mr Hitoshi Mukai and his staff at Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital for conducting insurance claim reviews.
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###### 

Transitional probabilities from healthy state to disease states in Markov model

                                                         **Placebo**  **Tamoxifen**                                        **Raloxifene**                                                                                                      
  ----------------------------------------------------- ------------- --------------------------------------------------- ---------------- ------------------ --------------------------------------------------- --------- ------------------ -----------------------------------------------------------------------------------------------------
  *Invasive breast cancer*                                                                                                                                                                                                                     
   Five-year predicted breast cancer risk ⩾1.66%                                                                                                                                                                                               
    Age of starting prophylaxis                                                                                                                                                                                                                
     35                                                    0.00632    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00404       0.00235--0.00641  [Fisher *et al* (2005)](#bib13){ref-type="other"}                                 
     50                                                    0.00587    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00333       0.00168--0.00573  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00310   0.00184--0.00490  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
     60                                                    0.00668    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00330       0.00165--0.00567  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00366   0.00213--0.00585  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   Five-year predicted breast cancer risk 3.01--5.00%      0.00451    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00270       0.00108--0.00534  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00203   0.00101--0.00349  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   Five-year predicted breast cancer risk ⩾5.01%           0.01198    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00515       0.00245--0.00893  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00561   0.00323--0.00894  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   History of lobular carcinoma *in situ*                  0.01170    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00627       0.00161--0.01476  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00614   0.00239--0.01226  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   History of atypical hyperplasia                         0.01042    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00255       0.00029--0.00686  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00286   0.00133--0.00523  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
  Noninvasive breast cancer                                0.00012    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00004       0.00000--0.00652  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00006   0.00003--0.00009  [Fisher *et al* (2005](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
                                                                                                                                                                                                                                                
  *Endometrial cancer*                                                                                                                                                                                                                         
   Age of starting prophylaxis                                                                                                                                                                                                                 
    35                                                     0.00082    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00116       0.00010--0.00410  [Fisher *et al* (2005)](#bib13){ref-type="other"}                                 
    50 and 60                                              0.00058    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00308       0.00061--0.00992  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00194   0.00065--0.00403  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
                                                                                                                                                                                                                                                
  *Pulmonary embolism*                                                                                                                                                                                                                         
   Age of starting prophylaxis                                                                                                                                                                                                                 
    35                                                     0.00013    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00025       0.00000--0.00420  [Fisher *et al* (2005)](#bib13){ref-type="other"}                                 
    50 and 60                                              0.00044    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00096       0.00020--0.00275  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00061   0.00028--0.00114  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   Cataract                                                0.02285    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.02775       0.02384--0.03206  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.02192   0.01735--0.02734  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}
   Hip fracture                                            0.00086    [Fisher *et al* (2005)](#bib13){ref-type="other"}       0.00059       0.00022--0.00122  [Fisher *et al* (2005)](#bib13){ref-type="other"}    0.00052   0.00016--0.00115  [Fisher *et al* (2005)](#bib13){ref-type="other"}, [Vogel *et al* (2006)](#bib45){ref-type="other"}

1.5 times of 95% confidence interval.

###### 

Assumptions used in Markov model

                                                                   **Assumption**                                                                                                  **Range tested in sensitivity analysis**   **Source**
  ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------
  *Transitional probabilities from disease states to dead state*                                                                                                                                                              
   Invasive breast cancer                                          0--9 years after diagnosis: prognosis of Japanese breast cancer patients by the stage                           Change by±50%                              Calculated from follow-up patients at Komagome Hospital
                                                                    Stage I: 0.0074, 0.0155, 0.0113, 0.0218, 0.0254, 0.0248, 0.0289, 0.0165, 0.01632                                                                           
                                                                    Stage II: 0.0054, 0.0474, 0.0570, 0.0334, 0.0398, 0.0321, 0.0275, 0.0295, 0.04672                                                                          
                                                                    (Proportions of stage at diagnosis are assumed stage I as 72% and stage II as 28%)                             Change by±50%                              [Japan Cancer Society (2007)](#bib23){ref-type="other"}
                                                                   Thereafter: Japanese female population mortality rates                                                          Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
   Noninvasive breast cancer                                       Japanese female population mortality rates                                                                      Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
   Endometrial cancer                                              0--4 years after diagnosis: prognosis of Japanese endometrial cancer patients 0.0660, 0.0546, 0.0328, 0.02813   Change by±50%                              [Japanese Society of Obstetrics and Gynecology (2000)](#bib24){ref-type="other"}
                                                                   Thereafter: Japanese female population mortality rates                                                          Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
   Pulmonary embolism                                              0 year after diagnosis: 0.08                                                                                    Change by±50%                              [Sakuma *et al* (2004)](#bib38){ref-type="other"}
                                                                   Thereafter: Japanese female population mortality rates                                                          Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
   Cataracts                                                       Japanese female population mortality rates                                                                      Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
   Hip fracture                                                    0--1 years after diagnosis: 0.11 and 0.19, respectively                                                         Change by±50%                              [Kitamura *et al* (1998)](#bib26){ref-type="other"}
                                                                   Thereafter: Japanese female population mortality rates                                                          Change by±50%                              [Ministry of Health, Labour and Welfare (2005a)](#bib30){ref-type="other"}
                                                                                                                                                                                                                               
  *Utility weights*                                                                                                                                                                                                            
   Healthy                                                         1.00                                                                                                            Change by±20%                               
    Healthy under chemoprevention for 5 years                      0.99                                                                                                            Change by±20%                              [Smith and Hillner (1993)](#bib39){ref-type="other"}, [Hillner *et al* (1993)](#bib21){ref-type="other"}, Naeim and Keeler (2005)
   Invasive breast caner                                           0 year after diagnosis: 0.87, thereafter: 0.89                                                                  Change by±20%                              [de Koning *et al* (1991](#bib8){ref-type="other"}), [Grann *et al* (1998)](#bib18){ref-type="other"}
   Noninvasive breast cancer                                       0.98                                                                                                            Change by±20%                              [Earle *et al* (2000)](#bib11){ref-type="other"}
   Endometrial cancer                                              0 year after diagnosis: 0.83, thereafter: 0.88                                                                  Change by±20%                              [Armstrong *et al* (2001)](#bib1){ref-type="other"}, [Cykert *et al* (2004)](#bib7){ref-type="other"}
   Pulmonary embolism                                              0.70                                                                                                            Change by±20%                              [Chau *et al* (2003)](#bib4){ref-type="other"}
   Cataract surgery                                                0.96                                                                                                            Change by±20%                              [Ruof *et al* (2005)](#bib37){ref-type="other"}
   Hip fracture                                                    0--1 years after diagnosis: 0.61 and 0.92, respectively                                                         Change by±20%                              [Armstrong *et al* (2001)](#bib1){ref-type="other"}

###### 

Costs (¥)

                                                                                             **Healthy**       **Breast cancer**                                                                                                                                                                                               
  ------------------------------------------------------------------------------------- --------------------- ------------------- ----------------------------------------------------------------------------------------------------------------------- ---------- --------------------------------------------------------- ------------------------
  *Chemoprevention*                                                                                                                                                                                                                                                                                                             
   Tamoxifen                                                                                   30 149            Change by±50%                                                     Drug price list, etc                                                                                                                         
   Raloxifene                                                                                  54 203            Change by±50%                                                                                                                                                                                                  
   Prescription+annual mammography                                                             44 980            Change by±50%                                                                                                                                                                                                  
   Annual mammography                                                                          15 520            Change by±50%                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                
  *Ages 35--49*                                                                                                                                                                                                                                                                                                                 
   First year after diagnosis                                                                                                                                                                                                                              1978 064  Change by±50%                                              
   Yearly cost                                                                                                                                                                                                                                             383 743   Change by±50%                                              
    Ages 35--39                                                                                81 937            Change by±50%                                                                                                                                                                                                  
    Ages 40--44                                                                                94 529            Change by±50%     [Ministry of Health, Labour and Welfare (2005b](#bib31){ref-type="other"}), [Fukawa (1998)](#bib15){ref-type="other"}                                                                       Insurance claim review
    Ages 45--49                                                                                110 604           Change by±50%                                                                                                                                                                                                  
   Terminal care cost, last year of life                                                                                                                                                                                                                   5495 224  Change by±50%                                              
    Ages 35--39                                                                                352 331           Change by±50%                                                                                                                                                                                                  
    Ages 40--44                                                                                406 474           Change by±50%                                                                                                                                                                                                  
    Ages 45--49                                                                                475 599           Change by±50%                                                                                                                                       Change by±50%                                              
                                                                                                                                                                                                                                                                                                                                
  *Ages 50--64*                                                                                                                                                                                                                                                                                                                 
   First year after diagnosis                                                                                                                                                                                                                              2211 083  Change by±50%                                              
   Yearly cost                                                                                                                                                                                                                                             542 857   Change by±50%                                              
    Ages 50--54                                                                                151 625           Change by±50%     [Ministry of Health, Labour and Welfare (2005b](#bib31){ref-type="other"}), [Fukawa (1998)](#bib15){ref-type="other"}                                                                       Insurance claim review
    Ages 55--59                                                                                195 085           Change by±50%                                                                                                                                                                                                  
    Ages 60--64                                                                                258 723           Change by±50%                                                                                                                                                                                                  
   Terminal care cost, last year of life                                                                                                                                                                                                                   4106 271  Change by±50%                                              
    Ages 50--54                                                                                651 986           Change by±50%                                                                                                                                                                                                  
    Ages 55--59                                                                                838 866           Change by±50%                                                                                                                                                                                                  
    Ages 60--64                                                                               1112 510           Change by±50%                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                
  *Ages 65--79*                                                                                                                                                                                                                                                                                                                 
   First year after diagnosis                                                                                                                                                                                                                              1530 259  Change by±50%                                              
   Yearly cost                                                                                                                                                                                                                                             441 458   Change by±50%                                              
    Ages 65--69                                                                                324 347           Change by±50%                                                                                                                                                                                                  
    Ages 70--74                                                                                460 617           Change by±50%     [Ministry of Health, Labour and Welfare (2005b](#bib31){ref-type="other"}), [Fukawa (1998)](#bib15){ref-type="other"}                                                                       Insurance claim review
    Ages 75--79                                                                                549 284           Change by±50%                                                                                                                                                                                                  
   Terminal care cost, last year of life                                                                                                                                                                                                                   3252 302  Change by±50%                                              
    Ages 65--69                                                                               1394 690           Change by±50%                                                                                                                                                                                                  
    Ages 70--74                                                                               1980 653           Change by±50%                                                                                                                                                                                                  
    Ages 75--79                                                                               2361 923           Change by±50%                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                
  *Ages 80+*                                                                                                                                                                                                                                                                                                                    
   First year after diagnosis                                                                                                      [Ministry of Health, Labour and Welfare (2005b](#bib31){ref-type="other"}), [Fukawa (1998)](#bib15){ref-type="other"}   961 181   Change by±50%                                             Insurance claim review
   Yearly cost                                                                                                                                                                                                                                             185 151   Change by±50%                                              
    Ages 80--84                                                                                576 290           Change by±50%                                                                                                                                                                                                  
    Ages 85--89                                                                                647 941           Change by±50%                                                                                                                                                                                                  
    Ages 90--94                                                                                557 429           Change by±50%                                                                                                                                                                                                  
    Ages 95--100                                                                               465 059           Change by±50%                                                                                                                                                                                                  
   Terminal care cost, last year of life                                                                                                                                                                                                                   427 042   Change by±50%                                              
    Ages 80--84                                                                               2478 049           Change by±50%                                                                                                                                                                                                  
    Ages 85--89                                                                               2786 147           Change by±50%                                                                                                                                                                                                  
    Ages 90--94                                                                               2396 943           Change by±50%                                                                                                                                                                                                  
    Ages 95--100                                                                              1999 754           Change by±50%                                                                                                                                                                                                  
                                                                                            **Diseases**                                                                                                                                                                                                                       
                                                                                         **Base-case value**                                                             **Range tested in sensitivity analysis**                                                    **Source**                                                 
  *Noninvasive breast cancer surgery, etc (DPC0900103x020xxx+ reimbursements by FFS)*          847 928                                                                                 Change by±50%                                                                 [Matsuda and Ishikawa (2003)](#bib28){ref-type="other"}    
                                                                                                                                                                                                                                                                                                                                
  *Endometrial cancer*                                                                                                                                                                                                                                                                                                          
  Total hysterectomy, etc (DPC 1200203x01x0xx+ reimbursements by FFS)                         1183 839                                                                                 Change by±50%                                                                 [Matsuda and Ishikawa (2003)](#bib28){ref-type="other"}    
  *Pulmonary embolism*                                                                                                                                                                                                                                                                                                          
   Total                                                                                       469 890                                                                                                                                                                                                                          
   (Diagnosis)                                                                                (52 350)                                                                                 Change by±50%                                                                 [Fuji *et al* (2005)](#bib14){ref-type="other"}            
   (Treatment)                                                                                (417 540)                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                
  *Cataract*                                                                                                                                                                                                                                                                                                                    
   Surgery, etc (DPC 0201103x01x 000+reimbursements by FFS)                                    309 120                                                                                 Change by±50%                                                                 [Matsuda and Ishikawa (2003)](#bib28){ref-type="other"}    
  *Hip fracture*                                                                                                                                                                                                                                                                                                                
   Surgery, etc (DPC 1608003x02xx0x+ reimbursements by FFS)                                   1553 195                                                                                 Change by±50%                                                                 [Matsuda and Ishikawa (2003)](#bib28){ref-type="other"}    

DPC: diagnosis procedure combination; FFS: fee for service.

###### 

Results of cost-effectiveness analysis (1)

                                                            **CoCost (¥)**     **Effectiveness (LYGs)**   **Effectiveness (QALYs)**   **Incremental cost- effectiveness ratio**                                                                                                                    
  ------------------------------------------------------ -------------------- -------------------------- --------------------------- ------------------------------------------- ---------------- ----------------- -------------------- ---------------- ----------------- ---------------------- ----------------------
  *Five-year predicted breast cancer risk ⩾1.66%*                                                                                                                                                                                                                                                  
   Starting at age 35                                         13 958 679              13 983 626                   24 947                              25.916                         25.953            0.037              25.757             25.759            0.002              678 210               14 247 447
   Starting at age 50                                         17 630 814              17 751 353                   120 538                             22.168                         22.167           −0.001              22.040             22.000           −0.040        Cost more, gain less   Cost more, gain less
   Starting at age 60                                         20 160 906              20 324 294                   163 388                             18.806                         18.807            0.001              18.688             18.654           −0.034            120 849 008        Cost more, gain less
                                                                                                                                                                                                                                                                                                              
  *Five-year predicted breast cancer risk 3.01--5.00%*                                                                                                                                                                                                                                             
   Starting at age 35                                         13 627 472              13 685 368                   57 896                              26.005                         26.035            0.030              25.879             25.872           −0.007             1 946 092         Cost more, gain less
   Starting at age 50                                         17 579 407              17 732 900                   153 493                             22.195                         22.185           −0.010              22.088             22.037           −0.051        Cost more, gain less   Cost more, gain less
   Starting at age 60                                         20 251 937              20 444 141                   192 203                             18.808                         18.797           −0.011              18.718             18.666           −0.052        Cost more, gain less   Cost more, gain less
                                                                                                                                                                                                                                                                                                              
  *Five-year predicted breast cancer risk ⩾5.01%*                                                                                                                                                                                                                                                  
   Starting at age 35                                         14 956 349              14 667 969                  −288 380                             25.651                         25.755            0.105              25.396             25.480            0.084        Cost less, gain more   Cost less, gain more
   Starting at age 50                                         17 867 146              17 800 766                   −66 379                             22.049                         22.096            0.047              21.832             21.854            0.022        Cost less, gain more   Cost less, gain more
   Starting at age 60                                         19 958 433              20 058 020                   99 857                              18.797                         18.825            0.028              18.614             18.618            0.004              3548 049              26 648 821
                                                                                                                                                                                                                                                                                                              
  *History of lobular carcinoma* *in situ*                                                                                                                                                                                                                                                         
   Starting at age 35                                         14 908 314              14 717 649                  −190 665                             25.663                         25.747            0.083              25.414             25.472            0.058        Cost less, gain more   Cost less, gain more
   Starting at age 50                                         17 856 158              17 850 722                   −5 386                              22.054                         22.085            0.031              21.841             21.843            0.002        Cost less, gain more   Cost less, gain more
   Starting at age 60                                         19 968 466              20 093 211                   124 745                             18.798                         18.815            0.017              18.618             18.606           −0.011              7282 700         Cost more, gain less
                                                                                                                                                                                                                                                                                                              
  *History of atypical hyperplasia*                                                                                                                                                                                                                                                                
   Starting at age 35                                         14 687 003              14 319 102                  −367 901                             25.722                         25.844            0.122              25.493             25.598            0.105        Cost less, gain more   Cost less, gain more
   Starting at age 50                                         17 806 095              17 692 020                  −114 075                             22.079                         22.139            0.060              21.884             21.922            0.038        Cost less, gain more   Cost less, gain more
   Starting at age 60                                         20 015 243              20 096 731                   81 488                              18.800                         18.837            0.037              18.635             18.651            0.016              2226 684             5234 647^a^
                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                              
  **No prophylaxis *vs* prophylaxis with raloxifene**     **No prophylaxis**        **Raloxifene**             **Incremental**                   **No prophylaxis**               **Raloxifene**   **Incremental**   **No prophylaxis**   **Raloxifene**   **Incremental**       **(¥/LYG)**            **(¥/QALY)**
  *Five-year predicted breast cancer risk ⩾1.66%*                                                                                                                                                                                                                                                  
   Starting at age 50                                         17 630 814              17 833 020                   202 206                             22.168                         22.190            0.022              22.040             22.027           −0.013              9256 382         Cost more, gain less
   Starting at age 60                                         20 160 906              20 427 386                   266 480                             18.806                         18.822            0.016              18.688             18.670           −0.018             16 806 286        Cost more, gain less
                                                                                                                                                                                                                                                                                                              
  *Five-year predicted breast cancer risk 3.01--5.00%*                                                                                                                                                                                                                                             
   Starting at age 50                                         17 579 407              17 794 890                   215 482                             22.195                         22.214            0.019              22.088             22.071           −0.017             11 599 422        Cost more, gain less
   Starting at age 60                                         20 251 937              20 529 452                   277 515                             18.808                         18.820            0.012              18.718             18.694           −0.024             23 845 594        Cost more, gain less
                                                                                                                                                                                                                                                                                                              
  *Five-year predicted breast cancer risk ⩾5.01%*                                                                                                                                                                                                                                                  
   Starting at age 50                                         17 867 146              17 911 198                   44 053                              22.049                         22.111            0.062              21.832             21.871            0.039              705 126              1123 880^a^
   Starting at age 60                                         19 958 433              20 161 888                   203 455                             18.797                         18.839            0.042              18.614             18.633            0.019              4848 677              10 664 954
                                                                                                                                                                                                                                                                                                              
  *History of lobular carcinoma* *in situ*                                                                                                                                                                                                                                                         
   Starting at age 50                                         17 856 158              17 935 697                   79 540                              22.054                         22.107            0.053              21.841             21.869            0.027              1496 425             2904 386^a^
   Starting at age 60                                         19 968 466              20 186 549                   218 083                             18.798                         18.833            0.036              18.618             18.628            0.010              6133 167              21462 765
                                                                                                                                                                                                                                                                                                              
  *History of atypical hyperplasia*                                                                                                                                                                                                                                                                
   Starting at age 50                                         17 806 095              17 795 708                   −10 387                             22.079                         22.156            0.077              21.884             21.942            0.058        Cost less, gain more   Cost less, gain more
   Starting at age 60                                         20 015 243              20 198 328                   183 085                             18.800                         18.852            0.052              18.635             18.668            0.033              3527 453             5570 154^a^

Cost-effective when compared to a suggested criterion in Japan ([Ohkusa, 2003](#bib34){ref-type="other"}) of ¥6000  000 for one QALY gain.

###### 

Results of cost-effectiveness analysis (2)

                                                          **Cost (¥)**   **Effectiveness (LYGs)**   **Effectiveness (QALYs)**   **Incremental cost-effectiveness ratio**                                                        
  ------------------------------------------------------ -------------- -------------------------- --------------------------- ------------------------------------------ -------- ------- -------- -------- ------- ---------- -------------
  *Five-year predicted breast cancer risk ⩾1.66%*                                                                                                                                                                               
   Starting at age 50                                      17 751 353           17 833 020                   81 667                              22.167                    22.190   0.023   22.000   22.027   0.027   3501 723   3035 955^a^
   Starting at age 60                                      20 324 294           20 427 386                   103 093                             18.807                    18.822   0.015   18.654   18.670   0.016   7107 875    6364 920
                                                                                                                                                                                                                                       
  *Five-year predicted breast cancer risk 3.01--5.00%*                                                                                                                                                                          
   Starting at age 50                                      17 732 900           17 794 890                   61 990                              22.185                    22.214   0.029   22.037   22.071   0.034   2163 079   1839 670^a^
   Starting at age 60                                      20 444 141           20 529 452                   85 312                              18.797                    18.820   0.023   18.666   18.694   0.028   3741 906   3063 477^a^
                                                                                                                                                                                                                                       
  *Five-year predicted breast cancer risk ⩾5.01%*                                                                                                                                                                               
   Starting at age 50                                      17 800 766           17 911 198                   110 432                             22.096                    22.111   0.015   21.854   21.871   0.017   7150 490    6542 190
   Starting at age 60                                      20 058 020           20 161 888                   103 869                             18.825                    18.839   0.014   18.618   18.633   0.015   7476 332    6771 100
                                                                                                                                                                                                                                       
  *History of lobular carcinoma* *in situ*                                                                                                                                                                                      
   Starting at age 50                                      17 850 772           17 935 697                   84 925                              22.085                    22.107   0.022   21.843   21.869   0.025   3846 426   3359 650^a^
   Starting at age 60                                      20 093 211           20 186 549                   93 338                              18.815                    18.833   0.018   18.606   18.628   0.022   5064 724   4311 015^a^
                                                                                                                                                                                                                                       
  *History of atypical hyperplasia*                                                                                                                                                                                             
   Starting at age 50                                      17 692 020           17 795 708                   103 688                             22.139                    22.156   0.018   21.922   21.942   0.019   5922 294   5320 037^a^
   Starting at age 60                                      20 096 731           20 198 328                   101 598                             18.837                    18.852   0.015   18.651   18.668   0.017   6637 332   5872 017^a^

Cost-effective when compared to a suggested criterion in Japan ([Ohkusa, 2003](#bib34){ref-type="other"}) of ¥6000 000 for one QALY gain.
